Keppra 750mg Tablet contains Levetiracetam, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam’s precise mechanism of action is not fully understood; however, it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Keppra is typically administered orally and is well-absorbed with rapid onset of action. The 750mg dosage is often prescribed as part of a titration regimen or maintenance therapy, depending on clinical response and tolerability. It is important to adhere to the prescribed dosing schedule to maintain therapeutic plasma levels and minimize breakthrough seizures. Common adverse effects may include somnolence, dizziness, headache, and fatigue, while serious side effects such as behavioral changes or hypersensitivity reactions require prompt medical attention. Keppra has a favorable pharmacokinetic profile with minimal drug interactions, making it suitable for use in combination with other antiepileptic drugs. Dose adjustments may be necessary in patients with renal impairment. Regular monitoring and consultation with a healthcare professional are essential to optimize treatment outcomes and ensure patient safety.